ArticleCancers2024

Pathologic Response and Survival after Neoadjuvant Chemotherapy with Bevacizumab Followed by Surgery for Clinical Stage II/IIIA Nonsquamous Non-Small-Cell Lung Cancer: Results from a Phase II Feasibility Study (NAVAL).

Yasuhiro Tsutani et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.